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Abstract
Background: Lichen sclerosus (LS) is a chronic inflammatory condition that is known to arise on the vulva.
Many women with LS report vulvar pain, often affecting a patient’s quality of life. In this study, the sexual
function of LS patients, with and without pain, was compared to control populations.
Materials and Methods: A case-control study to examine the relationship between LS and sexual dysfunction was
conducted. A total of 335 women presenting to the gynecology clinic were included in the study: 197 women with
biopsy confirmedLSwere compared to two control groups (95 asymptomaticwomenwere ‘‘healthy’’ controls and 43
women had vulvovaginal candidiasis) on self-reported current health complaints, medical and surgical history and
current symptoms such as pain and itching, type and frequency of sexual activity, and satisfactionwith sexual activity.
Results: Women with LS reported less frequent sexual activity than healthy controls (p= 0.007) and Candida
controls ( p= 0.04). Currently sexually active women with LS were significantly less likely to report vaginal
intercourse (71.6%) than healthy controls (89.0%, p=0.003) or Candida controls (100%, p=0.0003), even though
similar proportions of all three groups reported that vaginal intercourse was important. Satisfaction towards the
quality of current sexual activity was significantly lower among women with LS compared with both the healthy
and Candida control groups. 23.7% of women with LS reported that sexual activity was rarely or never satisfactory
as compared with 0% of healthy controls ( p<0.0001) and 6.5% of Candida controls ( p= 0.03).
Conclusion: Women with LS have less frequent sexual activity and less satisfying sexual activity when
compared with controls.
Introduction
L ichen sclerosus (LS) is a chronic, inflammatory skincondition with a tendency to affect the external genita-
lia.1 Lichen sclerosus often results in significant disfiguration
of the vulva. It is characterized by an array of symptoms that
impact a patient’s life both mentally and physically.
Lichen sclerosus may cause significant vulvar changes, often
resulting in disfiguration of the vulva, affecting quality of life. It
is plausible that anatomical changes resulting from this disease
process may result in sexual dysfunction. However, very little
research investigating the effects of vulvar LS on sexual dys-
function has been conducted. It is important to understand the
impact of LS on women’s lives in regard to their sexual activity.
The objective of this study was to determine whether LS
was associated with a higher prevalence of sexual dysfunc-
tion as compared with control groups consisting of women
presenting to a gynecology clinic for routine screening/
preventative care and women with Candida infections. We
hypothesized that women with LS experienced more sexual
dysfunction and were less satisfied with sexual activities
compared with women without lichen sclerosus.
Materials and Methods
A case-control study design was utilized to examine the
relationship between LS of the vulva and sexual dysfunction.
The study protocol was approved by the Institutional Review
Board of the University of Michigan Health System.
Inclusion of cases and controls
Three groups of patients were recruited: cases with lichen
sclerosus and two control groups. The cases and a vulvar
Candidiasis-specific control group were recruited from wo-
men presenting for care at the University of Michigan Center
for Vulvar Diseases. All cases had biopsy-confirmed lichen
sclerosus. Candida controls were included if no other vulvar
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pathology was identified and Candida was identified by ei-
ther microscopy examination or culture. The second control
group consisted of healthy controls sampled from women
presenting to a gynecology clinic for routine screening and
preventative care. The healthy controls had no other vulvar or
vaginal diagnoses and denied pelvic or vulvar pain on the
intake questionnaire. To further ensure comparability of
cases and controls on the primary outcome of interest, the
study population was limited to women of reproductive age
(18–45 years). The final sample included 197 lichen sclerosus
cases, 95 healthy controls, and 43 Candida controls.
Intake questionnaire
Subjects self-completed an intake questionnaire addressing
current health complaints, medical and surgical history and
current symptoms such as pain and itching, type and frequency
of sexual activity, and satisfactionwith sexual activity. For those
with pain, the level and quality of pain were measured using a
modified version of the McGill pain scale.2,3 Sexual practices
were assessed using closed-ended items addressing the type
(oral, vaginal, or anal) and frequency of each of these activities.
Quality of current sexual activity was categorized as ‘‘never or
rarely satisfactory’’ or ‘‘sometimes or generally very satisfac-
tory.’’ Frequency of orgasm was categorized as never/infre-
quently, sometimes, or always. Interest in sex was assessed on a
five-point scale from 1 (no interest) to 5 (high interest); for
analysis purposes, this was categorized as not interested (1–2),
neutral (3), or interested (4–5). Importance of vaginal sexual
activity was assessed on a five-point scale, from 1 (not impor-
tant) to 5 (very important); for analysis purposes, this was cat-
egorized as not important (1–2), neutral (3), or important (4–5).
Statistical analysis
Demographic characteristics of cases and healthy controls and
Candida controls were compared using chi-squared tests for
categorical variables and Student t-tests for continuous vari-
ables. Self-reported vulvar pain was compared between cases
andCandida controls using a Fisher’s exact test. Healthy controls
were not compared with cases on vulvar pain because they were
selected based on a response of ‘‘no’’ to the vulvar pain question.
Self-reported sexual behaviors were compared between cases
and both control groups using chi-squared tests. Discordance of
self-reported attitudes towards sexual activity and actual sexual
behaviors were compared using chi-squared tests or Fisher’s
exacts tests where appropriate. All p-values were two-sided and
were considered statistically significant at p<0.05.
Results
A total of 335womenmet our inclusion criteria: 197women
with LS (cases), 95 asymptomatic women (healthy controls),
and 43 women with vulvovaginal candidiasis (Candida con-
trols). Over three-fourths (76.1%) of cases and 88.4% of
Candida controls reported current vulvar pain ( p= 0.14). De-
mographic characteristics of the cases and controls are
shown in Table 1. Women with LS were significantly older
Table 1. Demographic Characteristics of Lichen Sclerosus Cases and Controls of Reproductive Age (n = 335)
Characteristic
Overall
(N = 335) n (%)
Cases
(N = 197) n (%)
Healthy controls
(N = 95) n (%) p1
Candida controls
(N= 43) n (%) p2
Age (mean, SD) 32.3 (7.3) 35.4 (6.1) 29.5 (7.3) < 0.0001 33.8 (6.4) 0.19
Race < 0.0001 0.10
Caucasian 243 (72.5) 139 (70.6) 68 (71.6) 36 (83.7)
African American 19 (5.7) 4 (2.0) 13 (13.7) 2 (4.7)
Other 25 (7.5) 6 (3.1) 14 (14.7) 5 (11.6)
Missing 48 (14.3) 48 (24.4) 0 (0) 0 (0)
Relationship status < 0.0001 0.85
Single 53 (15.8) 17 (8.6) 32 (33.7) 4 (9.3)
Married/cohabitating/stable
relationship
242 (72.2) 155 (78.7) 52 (54.7) 35 (81.4)
Separated/divorced 23 (6.9) 11 (5.6) 9 (9.5) 3 (7.0)
Widowed 13 (3.9) 12 (6.1) 0 (0) 1 (2.3)
Missing 4 (1.2) 2 (1.0) 2 (2.1) 0 (0)
Education 0.51 0.91
Up to high school graduate 55 (16.4) 27 (13.7) 21 (22.1) 7 (16.3)
Some college/technical
or trade school
91 (27.2) 50 (25.4) 25 (26.3) 16 (37.2)
College graduate 76 (22.7) 37 (18.8) 29 (30.5) 10 (23.3)
Graduate or professional school 63 (18.8) 35 (17.8) 20 (21.1) 8 (18.6)
Missing 50 (14.9) 48 (24.4) 0 (0) 2 (4.7)
Household income ($) 0.008 0.08
< 10,000 20 (6.0) 6 (3.1) 14 (14.7) 0 (0)
10,000–29,999 45 (13.4) 19 (9.6) 17 (17.9) 9 (20.9)
30,000–50,000 59 (17.6) 26 (13.2) 21 (22.1) 12 (27.9)
> 50,000 141 (42.1) 84 (42.6) 40 (42.1) 17 (39.5)
Missing 70 (20.9) 62 (31.5) 3 (3.2) 5 (11.6)
1p-Value for comparison of characteristic between cases and healthy controls.
2p-Value for comparison of characteristic between cases and candida controls.
SD, standard deviation.
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( p< 0.0001), more likely to be married ( p< 0.0001) and of
higher household income ( p= 0.008) than the healthy controls.
The LS cases were similar to Candida controls with respect to
age, race, relationship status, education, and household income
(all p-values> 0.05).
Characteristics of sexual behavior including frequency, type,
and quality of sexual activity and frequency of orgasm are
shown in Table 2. Women with LS reported significantly less
frequent sexual activity than either healthy controls or Candida
controls ( p= 0.007 and p= 0.04 respectively). Although similar
proportions of the currently sexually active women in all three
study groups reported that vaginal sexual activity was impor-
tant, women with LS who were currently sexually active were
significantly less likely to report vaginal intercourse than either
healthy controls (71.6% vs. 89.0%, p= 0.003) or Candida
controls (100%, p= 0.0003) Satisfaction towards the quality of
current sexual activity was significantly lower among women
with LS compared to both healthy and Candida controls who
were currently sexually active: 23.7% of women with LS re-
ported that sexual activity was rarely or never satisfactory as
compared to none of the healthy controls ( p< 0.0001) and
6.5% of Candida controls ( p= 0.03). By contrast, sexually
active women with LS report less frequent orgasms than
healthy controls (p< 0.0001), but have similar rates of orgasm
as the Candida controls ( p= 0.22).
Discordance between attitudes towards sexual activity and
sexual behaviors of cases and controls is shown in Table 3. Of
the women with LS, 15.3% felt that vaginal sexual activity
was important but their current quality of sexual activity was
rarely or never satisfactory, compared with none of the
healthy controls ( p < 0.0001) and 4.7% of the Candida con-
trols ( p= 0.07).
Table 2. Characteristics of Sexual Behavior Among Cases and Controls of Reproductive Age
Characteristic
Overall
n (%)
Cases
n (%)
Healthy
controls n (%) p1
Candida
controls p2
Frequency of sexual activity, all
participants (N= 335)
0.007 0.04
Never sexually active 20 (6.0) 12 (6.1) 8 (8.4) 0 (0)
Less than once per week 128 (38.2) 86 (43.7) 30 (31.6) 12 (27.9)
At least once per week 133 (39.7) 62 (31.5) 52 (54.7) 19 (44.2)
Missing 54 (16.1) 37 (18.8) 5 (5.3) 12 (27.9)
Type of current sexual activity,3 currently
sexually active participants (N = 261)
Vaginal sex 210 (80.5) 106 (71.6) 73 (89.0) 0.003 31 (100) 0.0003
Oral sex 132 (50.6) 63 (42.6) 44 (53.7) 0.11 25 (80.7) < 0.0001
Anal sex 15 (5.8) 6 (4.1) 5 (6.1) 0.49 4 (12.9) 0.07
Masturbation 73 (28.0) 31 (21.0) 31 (37.8) 0.006 11 (35.5) 0.08
Instruments for orgasm 35 (13.4) 15 (10.1) 12 (14.6) 0.31 8 (25.8) 0.02
Quality of current sexual activity, currently
sexually active participants (N = 261)
< 0.0001 0.03
Never or rarely satisfactory 37 (14.2) 35 (23.7) 0 (0) 2 (6.5)
Sometimes or generally very satisfactory 204 (78.2) 100 (67.6) 76 (92.7) 28 (90.3)
Missing 20 (7.7) 13 (8.8) 6 (7.3) 1 (3.2)
Frequency of orgasm, currently sexually
active participants (n = 261)
< 0.0001 0.22
Never/infrequently 32 (12.3) 25 (16.9) 2 (2.4) 5 (16.1)
Sometimes 76 (29.1) 65 (43.9) 0 (0.0) 11 (35.5)
Always 127 (48.7) 38 (25.7) 75 (91.5) 14 (45.2)
Missing 26 (10.0) 20 (13.5) 5 (6.1) 1 (3.2)
Interest in sex,4 currently sexually active
participants (N= 261)
0.01 0.14
Not interested 45 (17.2) 35 (23.7) 7 (8.5) 3 (9.7)
Neutral 78 (29.9) 42 (28.4) 27 (32.9) 9 (29.0)
Interested 131 (50.2) 65 (43.9) 47 (57.3) 19 (61.3)
Missing 7 (2.7) 6 (4.1) 1 (1.2) 0 (0)
Importance of vaginal sexual activity,5 currently
sexually active participants (N = 261)
0.20 0.17
Not important 29 (11.1) 17 (11.5) 11 (13.4) 1 (3.2)
Neutral 59 (22.6) 30 (20.3) 25 (30.5) 4 (12.9)
Important 164 (62.8) 94 (63.5) 44 (53.7) 26 (83.9)
Missing 9 (3.5) 7 (4.7) 2 (2.4) 0 (0)
1p-Value for comparison of characteristic between cases and controls.
2p-Value for comparison of characteristic between cases and Candida controls.
3Types are not mutually exclusive (participants could indicate more than one type of sexual activity).
4Scale of 1 (no interest) to 5 (high interest), categorized as interested (4–5), neutral (3) or not interested (1–2).
5Scale of 1 (not important) to 5 (very important), categorized as important (4–5), neutral (3) or not important (1–2).
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Discussion
Lichen sclerosus of the vulva is a chronic condition af-
fecting women throughout their lifespan. The pathophysiology
of LS is unknown; however, various genetic, autoimmune, and
local factors have been implicated. The cause is probably
multifactorial. The majority of descriptive studies on LS have
focused mainly on vulvar pruritus and irritation; however,
other symptoms may be present. Vulvar LS has been asso-
ciated with numerous bladder, bowel, and other pain co-
morbidities including dyspareunia, burning sensation, and
dysuria.4,5 Vulvar scarring often occurs, at times resulting in
problems with intercourse. In patients with advanced dis-
ease, the introitus may become narrowed resulting in painful
sexual intercourse or preventing intercourse altogether.6
The relationships between vulvar pain, sexual dysfunction,
and LS are poorly understood. These symptoms are present
for many women suffering from this disease.7,8 Studies have
evaluated LS and pain showing a significant impact on a
woman’s quality of life.5,9–20
Limited data are available focusing specifically on the
effect of LS on quality of life (QoL) and sexual function. Two
studies have shown that patients with LS report significant
impact on all major QoL domains (including those related to
sexual issues) except school/studying and work.7,21 The re-
sults from our subjects suggest a similar negative influence of
LS on sexual function as was shown in these other studies.
van de Nieuwenhof and colleagues explored details of sexual
function in women with LS and healthy controls, demon-
strating that subjects with LS reported significantly lower
sexual satisfaction and function than controls.7 Although
these findings are similar to those from our study, there are
several notable differences in the study methodologies that
need to be highlighted. Their group recruited women with
self-reported LS, whereas the subjects in our study all had
documented biopsy-proven disease. Furthermore, the healthy
controls in the study by van de Nieuwenhof were friends of
patients with dermatologic diseases, whereas our controls
were women presenting for routine health maintenance ex-
aminations in the gynecology clinic. Their participants were
also older than our subjects.
Little research has focused on describing the severity and
character of vulvar pain or the characteristics of sexual ac-
tivity in LS patients compared with healthy individuals. In a
questionnaire of 45 women analyzed with the diagnosis of
LS, 75.5% of them reported dyspareunia and reduced fre-
quency of intercourse; with apareunia in 42.2%.8 LeFevre,
et al., similarly found that substantial proportions of women
with LS reported dyspareunia, vulvar burning, and vulvar
pain, with complete symptom relief after treatment ranging
from approximately 47%–92%.9 Patient discomfort due to
the physical effects of LS is the likely cause of sexual dys-
function in these women. Lichen sclerosus may cause ero-
sions, fissures, scarring, labial fusion, and introital stenosis
that impacts women’s lives in regards to their sexual activity
and level of vulvar pain.21 Our study represents a comparison
between LS patients, with and without pain, to control pop-
ulations of gynecological patients without vulvar pathology
and women with vulvovaginal Candida infections. Although
similar proportions of the LS patients and Candida controls in
our study reported vulvar pain, the women with lichen
sclerosus report less frequent sexual activity and lower sexual
satisfaction. Possible explanations for this discrepancy in-
clude differences in the quality of pain experienced by these
two groups of women, anatomic changes associated with LS
but not with vulvar Candidiasis, differences in psychological
distress and/or satisfaction with genital appearance related to
these diseases, and duration of these diseases.
Numerous studies suggest that topical treatments may be
effective for pain control in women with LS. However, these
same treatments may not result in improved sexual function.
For example, two different studies have shown that topical
immunomodulators result in significant symptomatic relief
and histopathologic improvement, yet substantial proportions
of women using these treatments report persistent sexual
dysfunction.8,22
To further explore sexual dysfunction, the current study
analyzed the frequency, type, and quality of sexual activity
Table 3. Discordant Attitudes and Sexual Behaviors of Lichen Sclerosus Cases
and Controls of Reproductive Age (n = 335)
Overall
(n = 335)
n (%)
Cases
(n = 197)
n (%)
Healthy
controls
(n= 95) n (%) p1
Candida
controls
(n = 43) n (%) p2
I am interested in sexual activity,
but I am not currently engaging
in vaginal sexual intercourse.
33 (9.9) 21 (10.7) 9 (9.5) 0.46 3 (7.0) 0.58
I am interested in sexual activity,
but my current quality of sexual
activity is rarely or never satisfactory.
18 (5.4) 18 (9.1) 0 (0) < 0.0013 0 (0) 0.053
Vaginal sexual activity is important
to me, but I am not currently engaging
in vaginal sexual intercourse.
41 (12.2) 30 (15.2) 8 (8.4) 0.04 3 (7.0) 0.213
Vaginal sexual activity is important to me,
but my current quality of sexual activity
is rarely or never satisfactory.
32 (9.6) 30 (15.3) 0 (0) < 0.00013 2 (4.7) 0.073
1Chi-squared p-Value for comparison between cases and healthy controls.
2Chi-squared p-Value for comparison between cases and candida controls.
3Fisher’s exact test p-Value.
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and the quality and orgasms compared with a control group.
Lichen sclerosus cases were less frequently sexually active
than either of the control groups. Those patients with LS that
were sexually active were significantly less likely to report
vaginal intercourse than either healthy controls or Candida
controls. Several strategies exist for managing the patient
with lichen sclerosus and sexual dysfunction.23,24 LS may
cause scarring, labial fusion, and introital stenosis, at times
requiring surgical treatment.25–27 Unfortunately, despite
treatment for lichen sclerosus, a recent study found that
women with LS continue to have significant sexual dys-
function.22 The impact of LS on quality of life by inducing
dyspareunia and reducing interest for sexual engagement
because of pain requires further investigation.28 More re-
search is also needed to explore whether specifically target-
ing LS-associated pain effectively treats sexual dysfunction.
At this time, it is also unclear if increasing awareness of the
possibility of sexual dysfunction among patients with lichen
sclerosus results in in earlier intervention, and if this im-
proves their quality of life.
One limitation to this study is that the age, race, relation-
ship status and household income were significantly different
when comparing cases to healthy controls. Another limitation
is that while we are confident of the case definition, the re-
ferral patterns to a specialty clinic may pose some issue for
generalizing of these findings to all women with lichen
sclerosus. Despite these limitations, we have confirmed that it
is important to evaluate the impact of LS on sexual function,
emphasizing the need for health care providers to address
sexual function when treating patients with LS.
Conclusions
Our findings suggest that women with vulvar lichen
sclerosus suffer from a greater degree of sexual dysfunction
than both healthy women and those with Candida infections.
This study highlights the need for attention to sexual func-
tioning when treating patients with lichen sclerosus.
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